Oral delivery for hemoglobin based oxygen carriers
AssigneeBillion King International Limited
InventorsBing Lou Wong, Sui Yi Kwok
Life of this patent
Estimating the term…
Loading patent…
AssigneeBillion King International Limited
InventorsBing Lou Wong, Sui Yi Kwok
Estimating the term…
A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders. In addition to delivering oxygen, the heme group of hemoglobin from HBOC formulations can provide heme iron to the human body to aid in the production of more red blood cells.
An oral hemoglobin based oxygen carrier delivery system configured to release a hemoglobin based oxygen carrier in the intestinal tract of a patient such that the hemoglobin is delivered to the patient's bloodstream in a substantially undegraded form, the system including an enteric-coated capsule or tablet surrounding a pharmaceutical composition comprising a nanoparticle solution including hemoglobin-loaded nanoparticles, the hemoglobin-based oxygen carrier comprising one or more of purified hemoglobin, cross-linked hemoglobin, non-polymeric tetrameric hemoglobin, polymeric hemoglobin, or conjugated hemoglobin, and the hemoglobin-loaded nanoparticles being embedded into a polyelectrolyte complex under an aqueous-based condition at room temperature via polyelectrolyte complexation to result in a plurality of positively charged hemoglobin-loaded nanoparticles having an average particle size equal to or more than 150 nm, a zeta potential of 41±10 mV, and an encapsulation efficiency of about 28.7% or more.
Dependencies are inferred from the claim text.